Login to Your Account



Regulatory NEWS

As breakthroughs in regenerative medicine advance, the FDA finds itself in a balancing act in delivering on the transformative promise of stem cell and gene therapies while minimizing the risk and misleading hype.

BOGOTA, Colombia – Efforts to streamline and speed up drug approvals in Colombia are proving effective, with a new committee focused on new molecules and biologics moving applications forward at a rapid pace.

Envisioning the potential of CRISPR to cure cancers, sickle cell anemia, eye diseases and possibly even Alzheimer's, members of the Senate HELP Committee searched for ways Congress could help advance the technology while ensuring ethical standards and safeguarding against unintended consequences.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: